Domenico Tricò1,2, Alessandro Mengozzi3, Lorenzo Nesti3, Mensud Hatunic4, Rafael Gabriel Sanchez5, Thomas Konrad6, Katarina Lalić7, Nebojša M Lalić7, Andrea Mari8, Andrea Natali3. 1. Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56126, Pisa, Italy. domenico.trico@for.unipi.it. 2. Institute of Life Sciences, Sant'Anna School of Advanced Studies, Pisa, Italy. domenico.trico@for.unipi.it. 3. Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, 56126, Pisa, Italy. 4. Department of Endocrinology, Mater Misericordiae University Hospital, University College Dublin School of Medicine, Dublin, Ireland. 5. Unidad de Investigacion, Hospital Universitario de la Princesa, Madrid, Spain. 6. Institute for Metabolic Research, Goethe University, Frankfurt am Main, Germany. 7. Faculty of Medicine, University of Belgrade, Belgrade, Serbia. 8. Institute of Neuroscience, National Research Council, Padua, Italy.
Abstract
AIMS/HYPOTHESIS: Experimental studies suggest that the fatty acid palmitoleate may act as an adipocyte-derived lipid hormone (or 'lipokine') to regulate systemic metabolism. We investigated the relationship of circulating palmitoleate with insulin sensitivity, beta cell function and glucose tolerance in humans. METHODS: Plasma NEFA concentration and composition were determined in non-diabetic individuals from the Relationship between Insulin Sensitivity and Cardiovascular disease (RISC) study cohort at baseline (n = 1234) and after a 3 year follow-up (n = 924). Glucose tolerance, insulin secretion and beta cell function were assessed during an OGTT. Whole-body insulin sensitivity was measured by a hyperinsulinaemic-euglycaemic clamp (M/I) and OGTT (oral glucose insulin sensitivity index [OGIS]). The liver insulin resistance index was calculated using clinical and biochemical data. Body composition including fat mass was determined by bioelectrical impedance. RESULTS: Circulating palmitoleate was proportional to fat mass (r = 0.21, p < 0.0001) and total NEFA levels (r = 0.19, p < 0.0001). It correlated with whole-body insulin sensitivity (M/I: standardised regression coefficient [std. β] = 0.16, p < 0.0001), liver insulin resistance (std. β = -0.14, p < 0.0001), beta cell function (potentiation: std. β = 0.08, p = 0.045) and glucose tolerance (2 h glucose: std. β = -0.24, p < 0.0001) after adjustment for age, sex, BMI, adiposity and other NEFA. High palmitoleate concentrations prevented the decrease in insulin sensitivity associated with excess palmitate (p = 0.0001). In a longitudinal analysis, a positive independent relationship was observed between changes in palmitoleate and insulin sensitivity over time (std. β = 0.07, p = 0.04). CONCLUSIONS/ INTERPRETATION: We demonstrated that plasma palmitoleate is an independent determinant of insulin sensitivity, beta cell function and glucose tolerance in non-diabetic individuals. These results support the role of palmitoleate as a beneficial lipokine released by adipose tissue to prevent the negative effects of adiposity and excess NEFA on systemic glucose metabolism.
AIMS/HYPOTHESIS: Experimental studies suggest that the fatty acid palmitoleate may act as an adipocyte-derived lipid hormone (or 'lipokine') to regulate systemic metabolism. We investigated the relationship of circulating palmitoleate with insulin sensitivity, beta cell function and glucose tolerance in humans. METHODS: Plasma NEFA concentration and composition were determined in non-diabetic individuals from the Relationship between Insulin Sensitivity and Cardiovascular disease (RISC) study cohort at baseline (n = 1234) and after a 3 year follow-up (n = 924). Glucose tolerance, insulin secretion and beta cell function were assessed during an OGTT. Whole-body insulin sensitivity was measured by a hyperinsulinaemic-euglycaemic clamp (M/I) and OGTT (oral glucose insulin sensitivity index [OGIS]). The liver insulin resistance index was calculated using clinical and biochemical data. Body composition including fat mass was determined by bioelectrical impedance. RESULTS: Circulating palmitoleate was proportional to fat mass (r = 0.21, p < 0.0001) and total NEFA levels (r = 0.19, p < 0.0001). It correlated with whole-body insulin sensitivity (M/I: standardised regression coefficient [std. β] = 0.16, p < 0.0001), liver insulin resistance (std. β = -0.14, p < 0.0001), beta cell function (potentiation: std. β = 0.08, p = 0.045) and glucose tolerance (2 h glucose: std. β = -0.24, p < 0.0001) after adjustment for age, sex, BMI, adiposity and other NEFA. High palmitoleate concentrations prevented the decrease in insulin sensitivity associated with excess palmitate (p = 0.0001). In a longitudinal analysis, a positive independent relationship was observed between changes in palmitoleate and insulin sensitivity over time (std. β = 0.07, p = 0.04). CONCLUSIONS/ INTERPRETATION: We demonstrated that plasma palmitoleate is an independent determinant of insulin sensitivity, beta cell function and glucose tolerance in non-diabetic individuals. These results support the role of palmitoleate as a beneficial lipokine released by adipose tissue to prevent the negative effects of adiposity and excess NEFA on systemic glucose metabolism.
Authors: Haiming Cao; Kristin Gerhold; Jared R Mayers; Michelle M Wiest; Steven M Watkins; Gökhan S Hotamisligil Journal: Cell Date: 2008-09-19 Impact factor: 41.582
Authors: Kazuhisa Maeda; Haiming Cao; Keita Kono; Cem Z Gorgun; Masato Furuhashi; Kadir T Uysal; Qiong Cao; Genichi Atsumi; Harry Malone; Bala Krishnan; Yasuhiko Minokoshi; Barbara B Kahn; Rex A Parker; Gökhan S Hotamisligil Journal: Cell Metab Date: 2005-02 Impact factor: 27.287
Authors: Dariush Mozaffarian; Haiming Cao; Irena B King; Rozenn N Lemaitre; Xiaoling Song; David S Siscovick; Gökhan S Hotamisligil Journal: Am J Clin Nutr Date: 2010-10-13 Impact factor: 7.045
Authors: Amy E Griel; Yumei Cao; Deborah D Bagshaw; Amy M Cifelli; Bruce Holub; Penny M Kris-Etherton Journal: J Nutr Date: 2008-04 Impact factor: 4.798
Authors: Synnøve F Knutsen; Gary E Fraser; W Lawrence Beeson; Kristian D Lindsted; David J Shavlik Journal: Ann Epidemiol Date: 2003-02 Impact factor: 3.797
Authors: Alison J Eastman; Rebecca E Moore; Steven D Townsend; Jennifer A Gaddy; David M Aronoff Journal: Clin Ther Date: 2021-01-21 Impact factor: 3.393
Authors: Yu Liu; Alan Kuang; Octavious Talbot; James R Bain; Michael J Muehlbauer; M Geoffrey Hayes; Olga R Ilkayeva; Lynn P Lowe; Boyd E Metzger; Christopher B Newgard; Denise M Scholtens; William L Lowe Journal: Diabetologia Date: 2020-06-18 Impact factor: 10.122
Authors: Erin Vanessa LaRae Smith; Rebecca Maree Dyson; Christina M G Vanderboor; Ousseynou Sarr; Jane Anderson; Mary J Berry; Timothy R H Regnault; Lifeng Peng; Clint Gray Journal: Int J Mol Sci Date: 2022-01-17 Impact factor: 5.923